ZAI LAB LIMITED Debt Securities Held To Maturity Allowance For Credit Loss Excluding Accrued Interest
ZAI LAB LIMITED (ZLAB) had Debt Securities Held To Maturity Allowance For Credit Loss Excluding Accrued Interest of $0 as of 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Balance Sheet › Assets
us-gaap:DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest · last filed 2024-02-27
- 2023-12-31: Debt Securities Held To Maturity Allowance For Credit Loss Excluding Accrued Interest $0.00.
- 2021-12-31: Debt Securities Held To Maturity Allowance For Credit Loss Excluding Accrued Interest $0.00.
| Period end | Debt Securities Held To Maturity Allowance For Credit Loss Excluding Accrued Interest |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-27 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |